玻璃体腔内注射贝伐单抗治疗有新生血管的年龄相关性黄斑变性  

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

作　　者：Avery R.L. PieramiciD.J. RabenaM.D. 张少娟 

机构地区：[1]California Retina Consultants, 515 East Micheltorena Street, Santa Barbara, CA 93103, United States Dr.

出　　处：《世界核心医学期刊文摘（眼科学分册）》2006年第8期49-49,共1页Digest of the World Core Medical Journals:Ophthalmology

摘　　要：Purpose: To report the short-term safety, biologic effect, and a possible mechanism of action of intravitreal bevacizumab in patients with neovascular age-related macular degeneration (AMD). Design: Interventional, consecutive, retrospective case series. Participants: Eighty-one eyes of 79 patients with subfoveal neovascular AMD. Methods: Patients received intravitreal bevacizumab (1.25 mg) on a monthly basis until macular edema, subretinal fluid (SRF), and/or pigment epithelial detachment (PED) resolved. Ophthalmic evaluations included nonstandardized Snellen visual acuity (VA), complete ophthalmic examination, fluorescein angiography, and optical coherence tomography (OCT). Main Outcome Measures: Assessments of safety, changes in Snellen VA, OCT retinal thickness, and angiographic lesion characteristics were performed. Results: No significant ocular or systemic side effects were observed. Most patients (55% ) had a reduction of >10% of baseline retinal thickness at 1 week after the injection. At 4 weeks after injection, 30 of 81 eyes demonstrated complete resolution of retinal edema, SRF, and PEDs. Of the 51 eyes with 8 weeks’ follow-up, 25 had complete resolution of retinal thickening, SRF, and PEDs. At 1, 4, 8,and 12 weeks, the mean retinal thickness of the central 1 mm was decreased by 61, 92, 89, and 67 μ m, respectively (P<0.0001 for 1, 4, and 8 weeks and P<0.01 for 12 weeks). At 4 and 8 weeks, mean VA improved from 20/200 to 20/125 (P<0.0001). Median vision improved from 20/200 to 20/80- at 4 weeks and from 20/200 to 20/80 at 8 weeks. Conclusions: Short-term results suggest that intravitreal bevacizumab (1.25 mg) is well tolerated and associated with improvement in VA, decreased retinal thickness by OCT, and reduction in angiographic leakage in most patients, the majority of whom had previous treatment with photodynamic therapy and/or pegaptanib. Further evaluation of intravitreal bevacizumab for the treatment of choroidal neovascularization is warranted.Purpose: To report the short-term safety, biologic effect, and a possible mechanism of action of intravitreal bevacizumab in patients with neovascular age-related macular degeneration (AMD). Design: Interventional, consecutive, retrospective case series. Participants: Eighty-one eyes of 79 patients with subfoveal neovascular AMD. Methods: Patients received intravitreal bevacizumab (1.25 mg) on a monthly basis until macular edema, subretinal fluid (SRF), and/or pigment epithelial detachment (PED) resolved. Ophthalmic evaluations included nonstandardized Snellen visual acuity (VA), complete ophthalmic examination, fluorescein angiography, and optical coherence tomography (OCT). Main Outcome Measures: Assessments of safety, changes in Snellen VA, OCT retinal thickness, and angiographic lesion characteristics were performed. Results: No significant ocular or systemic side effects were observed. Most patients (55% ) had a reduction of >10% of baseline retinal thickness at 1 week after the injection. At 4 weeks after injection, 30 of 81 eyes demonstrated complete resolution of retinal edema, SRF, and PEDs. Of the 51 eyes with 8 weeks’ follow-up, 25 had complete resolution of retinal thickening, SRF, and PEDs. At 1, 4, 8,and 12 weeks, the mean retinal thickness of the central 1 mm was decreased by 61, 92, 89, and 67 μ m, respectively (P<0.0001 for 1, 4, and 8 weeks and P<0.01 for 12 weeks). At 4 and 8 weeks, mean VA improved from 20/200 to 20/125 (P<0.0001). Median vision improved from 20/200 to 20/80- at 4 weeks and from 20/200 to 20/80 at 8 weeks. Conclusions: Short-term results suggest that intravitreal bevacizumab (1.25 mg) is well tolerated and associated with improvement in VA, decreased retinal thickness by OCT, and reduction in angiographic leakage in most patients, the majority of whom had previous treatment with photodynamic therapy and/or pegaptanib. Further evaluation of intravitreal bevacizumab for the treatment of choroidal neovascularization is warranted.

关 键 词：腔内注射 贝伐单抗 视网膜厚度 色素上皮 黄斑水肿 中心凹 视网膜水肿 眼部检查 眼科检查 视网膜下 

分 类 号：R774.5[医药卫生—眼科]